[Retracted] Synergistic Effect of Stereotactic Radiotherapy Combined with Karelizumab on Patients with Advanced NSCLC

Table 6

Comparison of survival between two groups (n, %).

Groups	1-year survival rates	2-year survival rates	3-year survival rates
Control group (n = 54)	52 (96.30%)	39 (72.22%)	33 (61.11%)
Observation group (n = 46)	44 (95.65%)	41 (89.13%)	37 (80.43%)
χ^2	0.026	4.438	4.416
value	0.869	0.035	0.036